Mike Fisher Email

VP, Head Business Development . Oncimmune

Current Roles

Employees:
60
Revenue:
$9.3M
About
Oncimmune is a biotech company that specialises in blood tests and services that make use of the immune system. The EarlyCDT blood tests can detect cancer in the earliest stages when the body’s immune system is trying to fight it. The Company’s understanding of the immune system also means they’re able to work closely with pharmaceutical companies to ensure treatments, such as immunotherapy, are as effective and safe as possible.\n\nEarlyCDT Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
Oncimmune Address
One Broadway
1 Thane Road, null
UK
Oncimmune Email

Past Companies

OncimmuneVice President, Head of Business Development
OncimmuneCommercial Director
TechNation & BiotechNationEuropean Producer

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.